PlumX Metrics
Embed PlumX Metrics

A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma

Annals of Surgery, ISSN: 0003-4932, Vol: 249, Issue: 2, Page: 195-202
2009
  • 179
    Citations
  • 0
    Usage
  • 76
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    179
    • Citation Indexes
      177
    • Clinical Citations
      1
      • PubMed Guidelines
        1
    • Policy Citations
      1
      • Policy Citation
        1
  • Captures
    76
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma

STUDY INFORMATION OFFICIAL TITLE: A Randomized Controlled Trial of the Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma CURRENT STATUS: Not yet

Article Description

OBJECTIVE:: To evaluate the effect of preoperative transarterial chemoembolization (TACE) for resectable large hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA:: Resection of HCC is potentially curative, but local recurrence is very common. There is currently no effective neoadjuvant or adjuvant therapy. METHODS:: From July 2001 to December 2003, 108 patients (hepatitis B carrier ≤ 98.1%) with resectable HCC (ĝ‰¥5 cm) was randomly assigned to preoperative TACE treatment (n ≤ 52) or no preoperative treatment (control group) (n ≤ 56). RESULTS:: Five patients (9.6%) in the preoperative TACE group did not receive surgical therapy because of extrahepatic metastasis or liver failure. The preoperative TACE group had a lower resection rate (n ≤ 47, 90.4% vs. n ≤ 56, 100%; P≤ 0.017), and longer operative time (mean, 176.5 minutes vs. 149.3 minutes; P≤ 0.042). No significant difference was found between the 2 groups in operative blood loss, surgical morbidity, and hospital mortality.At a median follow-up of 57 months, 41 (78.8%) of 52 patients in the preoperative TACE group and 51 (91.1%) of 56 patients in the control group had recurrent disease (P≤ 0.087). The 1-, 3-, and 5-year disease-free survival rates were 48.9%, 25.5%, and 12.8%, respectively, for the preoperative TACE group and 39.2%, 21.4%, and 8.9%, respectively, for the control group (P≤ 0.372). The 1-, 3-, and 5-year overall survival rates were 73.1%, 40.4%, and 30.7%, respectively, for the preoperative TACE group and 69.6%, 32.1%, and 21.1%, respectively, for the control group (P≤ 0.679). CONCLUSIONS:: Preoperative TACE did not improve surgical outcome. It resulted in drop-out from definitive surgery because of progression of disease and liver failure. © 2009 by Lippincott Williams & Wilkins.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know